Trial Profile

A Multicenter Phase II Study Evaluating Denosumab (XGEVA®) in Combination with Nivolumab (OPDIVO®) As Second-line Therapy for Patients with Stage IV Non-small-cell Lung Cancer (squamous and Non-squamous) with Bone Metastases: DENIVOS STUDY

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Bone metastases; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms DENIVOS

13 Feb 2025 Status changed from active, no longer recruiting to completed.
25 Oct 2023 This trial has been completed in France(End Date: 19 Oct 2023), according to European Clinical Trials Database record.
13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com